FDA approves Ozempic to reduce the risk of kidney disease worsening, kidney failure and death due to CV disease in adults with type 2 diabetes and CKD Novo Nordisk Novo Nordisk announced that the FDA has approved Ozempic (semaglutide injection) to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD)
While results and side effects can vary, this medication is widely recognized as one of the most innovative options available for individuals seeking structured, medically guided weight support
ALKBH5-mediated CHAC1 depletion promotes malignant progression and decreases cisplatin-induced oxidative stress in gastric cancer
Miracle MIC B12 Supplement Benefits Your Health and Energy Levels
It mimics the action of the naturally occurring hormone GLP-1, which is produced in the intestines and plays a key role in regulating appetite, blood sugar, and metabolism
